Insider Trading Alert - Vertex Pharmaceuticals And 4 Others Traded By Insiders

Yesterday, July 5, 2013, 389 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $200.00 to $15,089,002.16.

Highlighted Stocks Traded by Insiders:

Vertex Pharmaceuticals (VRTX) - FREE Research Report

Mueller Peter who is EVP, Global R&D, CSO at VERTEX PHARM bought 254,938 shares at $38.41 per share for a total value of $13,525,842.90 on July 2, 2013. Following this transaction, the EVP, Global R&D, CSO owned 1.4 million shares meaning that the stake was boosted by 18.8% with the 254,938 share acquisition.

The shares most recently traded at $80.70, up $0.07, or 0.09% since the insider transaction. Historical insider transactions for Vertex Pharmaceuticals go as follows:

  • 4-Week # shares sold: 8,300
  • 12-Week # shares sold: 91,720
  • 24-Week # shares sold: 91,720

The average volume for Vertex Pharmaceuticals has been 2.6 million shares per day over the past 30 days. Vertex Pharmaceuticals has a market cap of $17.6 billion and is part of the health care sector and drugs industry. Shares are up 89.79% year to date as of the close of trading on Wednesday.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTX - FREE

TheStreet Quant Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

CommVault Systems (CVLT) - FREE Research Report

Bunte Al who is Executive Vice President & COO at COMMVAULT SYSTM sold 220 shares at $75.67 per share for a total value of $16,647.40 on July 2, 2013. Following this transaction, the Executive Vice President & COO owned 356,282 shares meaning that the stake was reduced by 0.06% with the 220 share sell-off.

Carolan Brian who is VP Finance and CFO at COMMVAULT SYSTM sold 75 shares at $75.67 per share for a total value of $5,675.25 on July 2, 2013. Following this transaction, the VP Finance and CFO owned 29,894 shares meaning that the stake was reduced by 0.25% with the 75 share sell-off.

Fanzilli Frank J who is Director at COMMVAULT SYSTM bought 3,200 shares on Oct. 25, 2012. Following this transaction, the Director owned 61,467 shares meaning that the stake was boosted by 5.49% with the 3,200 share acquisition.

Geday Armando who is Director at COMMVAULT SYSTM bought 3,200 shares on Oct. 25, 2012. Following this transaction, the Director owned 67,967 shares meaning that the stake was boosted by 4.94% with the 3,200 share acquisition.

Geeslin Keith who is Director at COMMVAULT SYSTM bought 3,200 shares on Oct. 25, 2012. Following this transaction, the Director owned 13,773 shares meaning that the stake was boosted by 30.27% with the 3,200 share acquisition.

Hammer N Robert who is Chairman, President & CEO at COMMVAULT SYSTM sold 288 shares at $75.67 per share for a total value of $21,792.96 on July 2, 2013. Following this transaction, the Chairman, President & CEO owned 2.4 million shares meaning that the stake was reduced by 0.01% with the 288 share sell-off.

Kurimsky Robert F who is Director at COMMVAULT SYSTM bought 3,200 shares on Oct. 25, 2012. Following this transaction, the Director owned 34,994 shares meaning that the stake was boosted by 10.06% with the 3,200 share acquisition.

Merrill Gary who is Chief Accounting Officer at COMMVAULT SYSTM sold 31 shares at $75.67 per share for a total value of $2,345.77 on July 2, 2013. Following this transaction, the Chief Accounting Officer owned 10,917 shares meaning that the stake was reduced by 0.28% with the 31 share sell-off.

Miceli Louis who is Senior VP of Finance at COMMVAULT SYSTM sold 125 shares at $75.67 per share for a total value of $9,458.75 on July 2, 2013. Following this transaction, the Senior VP of Finance owned 51,876 shares meaning that the stake was reduced by 0.24% with the 125 share sell-off.

Miiller Ronald L who is SVP, Worldwide Sales at COMMVAULT SYSTM sold 156 shares at $75.67 per share for a total value of $11,804.52 on July 2, 2013. Following this transaction, the SVP, Worldwide Sales owned 62,019 shares meaning that the stake was reduced by 0.25% with the 156 share sell-off.

Pulver Dan who is Director at COMMVAULT SYSTM bought 3,200 shares on Oct. 25, 2012. Following this transaction, the Director owned 47,367 shares meaning that the stake was boosted by 7.25% with the 3,200 share acquisition.

Smith Gary B who is Director at COMMVAULT SYSTM bought 3,200 shares on Oct. 25, 2012. Following this transaction, the Director owned 18,867 shares meaning that the stake was boosted by 20.43% with the 3,200 share acquisition.

Walker David F who is Director at COMMVAULT SYSTM bought 3,200 shares on Oct. 25, 2012. Following this transaction, the Director owned 12,867 shares meaning that the stake was boosted by 33.1% with the 3,200 share acquisition.

West David R who is SVP, Mkt & Bus. Development at COMMVAULT SYSTM sold 103 shares at $75.67 per share for a total value of $7,794.01 on July 2, 2013. Following this transaction, the SVP, Mkt & Bus. Development owned 34,542 shares meaning that the stake was reduced by 0.3% with the 103 share sell-off.

The shares most recently traded at $78.13, up $1.16, or 1.51% since the insider transactions. Historical insider transactions for CommVault Systems go as follows:

  • 4-Week # shares sold: 3,992
  • 12-Week # shares sold: 3,992
  • 24-Week # shares sold: 4,632

The average volume for CommVault Systems has been 565,500 shares per day over the past 30 days. CommVault Systems has a market cap of $3.5 billion and is part of the technology sector and computer software & services industry. Shares are up 8.41% year to date as of the close of trading on Wednesday.

CommVault Systems, Inc., together with its subsidiaries, provides data and information management software applications and related services primarily in North America, Europe, Australia, and Asia. The company has a P/E ratio of 68.7. Currently there are 6 analysts that rate CommVault Systems a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVLT - FREE

TheStreet Quant Ratings rates CommVault Systems as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full CommVault Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Pacira Pharmaceuticals (PCRX) - FREE Research Report

Wicki Andreas who is Director at PACIRA PHARMACT sold 114,448 shares at $30.12 per share for a total value of $3,457,072.80 on July 1, 2013. Following this transaction, the Director owned 5.9 million shares meaning that the stake was reduced by 1.91% with the 114,448 share sell-off.

The shares most recently traded at $30.91, up $0.13, or 0.42% since the insider transaction. Historical insider transactions for Pacira Pharmaceuticals go as follows:

  • 4-Week # shares bought: 853
  • 4-Week # shares sold: 22,746
  • 12-Week # shares bought: 853
  • 12-Week # shares sold: 22,746
  • 24-Week # shares bought: 853
  • 24-Week # shares sold: 2.3 million

The average volume for Pacira Pharmaceuticals has been 385,500 shares per day over the past 30 days. Pacira Pharmaceuticals has a market cap of $991.7 million and is part of the health care sector and drugs industry. Shares are up 71.78% year to date as of the close of trading on Wednesday.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Currently there are 5 analysts that rate Pacira Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PCRX - FREE

TheStreet Quant Ratings rates Pacira Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and generally high debt management risk. Get the full Pacira Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Procter & Gamble (PG) - FREE Research Report

Brown Bruce who is Chief Technology Officer at PROCTER & GAMBL bought 14,037 shares at $25.81 per share for a total value of $58,138.67 on July 1, 2013. Following this transaction, the Chief Technology Officer owned 43,603 shares meaning that the stake was boosted by 45.18% with the 14,037 share acquisition.

Fregolle Robert L. JR. who is Global Cust. Bus. Dev. Officer at PROCTER & GAMBL bought 8,310 shares at $19.36 per share for a total value of $57,674.18 on July 1, 2013. Following this transaction, the Global Cust. Bus. Dev. Officer owned 42,351 shares meaning that the stake was boosted by 23.39% with the 8,310 share acquisition.

Majoras Deborah P who is Chief Legal Officer & Secy at PROCTER & GAMBL sold 3,340 shares at $39.12 per share for a total value of $216,236.01 on July 1, 2013. Following this transaction, the Chief Legal Officer & Secy owned 12,633 shares meaning that the stake was reduced by 22.54% with the 3,340 share sell-off.

Passerini Filippo who is Grp Pres-CIO & Global Bus Svcs at PROCTER & GAMBL bought 15,417 shares at $15.48 per share for a total value of $57,287.10 on July 1, 2013. Following this transaction, the Grp Pres-CIO & Global Bus Svcs owned 104,128 shares meaning that the stake was boosted by 17.09% with the 15,417 share acquisition.

The shares most recently traded at $78.49, down $0.08, or 0.1% since the insider transactions. Historical insider transactions for Procter & Gamble go as follows:

  • 24-Week # shares sold: 2,400

The average volume for Procter & Gamble has been 10.1 million shares per day over the past 30 days. Procter & Gamble has a market cap of $215.0 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 15.73% year to date as of the close of trading on Wednesday.

The Procter & Gamble Company, together with its subsidiaries, engages in the manufacture and sale of a range of branded consumer packaged goods. The company operates in five segments: Beauty, Grooming, Health Care, Fabric Care and Home Care, and Baby Care and Family Care. The stock currently has a dividend yield of 3.07%. The company has a P/E ratio of 19.8. Currently there are 12 analysts that rate Procter & Gamble a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PG - FREE

TheStreet Quant Ratings rates Procter & Gamble as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, increase in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Procter & Gamble Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Graphic Packaging (GPK) - FREE Research Report

Scheible David W who is President & CEO at GRAPHIC PKG HLD sold 75,000 shares at $7.87 per share for a total value of $589,980.00 on July 1, 2013. Following this transaction, the President & CEO owned 932,773 shares meaning that the stake was reduced by 7.44% with the 75,000 share sell-off.

The shares most recently traded at $8.22, up $0.20, or 2.49% since the insider transaction. Historical insider transactions for Graphic Packaging go as follows:

  • 4-Week # shares sold: 75,000
  • 12-Week # shares sold: 3.1 million
  • 24-Week # shares sold: 9.9 million

The average volume for Graphic Packaging has been 1.9 million shares per day over the past 30 days. Graphic Packaging has a market cap of $2.8 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 24.15% year to date as of the close of trading on Wednesday.

Graphic Packaging Holding Company, together with its subsidiaries, provides packaging solutions in the United States, Canada, Central/South America, Europe, and the Asia-Pacific. The company operates in two segments, Paperboard Packaging and Flexible Packaging. The company has a P/E ratio of 21.7. Currently there are 5 analysts that rate Graphic Packaging a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GPK - FREE

TheStreet Quant Ratings rates Graphic Packaging as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, growth in earnings per share, increase in net income and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Graphic Packaging Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Cramer: 2017 Was a Year of Resurrection and Revival

Cramer: 2017 Was a Year of Resurrection and Revival

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting